The stock's fall snapped a two-day winning streak.

C3 AI (NYSE: AI), the Enterprise AI application software company, and Arcfield, a leading government technology and mission ...

ACCELQ, a leader in AI-powered test automation for enterprise applications, today unveiled significant enhancements to its Autopilot offering. Built on a sophisticated AI agent architecture, Autopilot ...

For Earth Day 2025, the award-winning app for scanning and managing documents, iScanner, launches a new feature for ...

The Nasdaq 100 index has crashed into a bear market this year amid AI and tariff fears. We explain why this is a good time to ...

Apple's next-generation M6 processor is being tested in new iPad Pros with new in-house C2/C3 5G modems that are aiming for a release sometime in 2027.

The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

Mysteries, from whence do they come and where hence do they go? I suppose if we knew the answers to those questions, we’d no ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...